

# Paolo Sportoletti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5091482/publications.pdf>

Version: 2024-02-01

109  
papers

5,319  
citations

185998

28  
h-index

85405

71  
g-index

110  
all docs

110  
docs citations

110  
times ranked

8389  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
2	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
3	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
4	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	3
5	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
6	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
7	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
8	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. <i>Leukemia</i> , 2022, , .	3.3	2
9	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	2.5	2
10	Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. <i>Leukemia</i> , 2021, 35, 1949-1963.	3.3	10
11	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
12	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
13	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
14	Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL. <i>Cancers</i> , 2021, 13, 1280.	1.7	14
15	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
16	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. <i>Leukemia</i> , 2021, 35, 2552-2562.	3.3	25
17	NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models. <i>Bone Marrow Transplantation</i> , 2021, 56, 2019-2023.	1.3	2
18	Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma. <i>Blood Cancer Discovery</i> , 2021, 2, 216-225.	2.6	22

#	ARTICLE	IF	CITATIONS
19	<sc><i>TP53</i></sc> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	2.0	8
20	<i>BCOR</i> gene alterations in hematologic diseases. Blood, 2021, 138, 2455-2468.	0.6	18
21	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	2.0	3
22	NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status. Frontiers in Oncology, 2021, 11, 668573.	1.3	4
23	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. Frontiers in Oncology, 2021, 11, 638689.	1.3	0
24	Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021042.	0.5	3
25	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 6665.	1.8	11
26	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 2021, 13, 3240.	1.7	16
27	Abstract LB044: Tracking clonal hematopoiesis in patients with classical Hodgkin lymphoma. , 2021, , .		1
28	Richter's transformation in the heart. Lancet Oncology, The, 2021, 22, e341.	5.1	2
29	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. Hematological Oncology, 2021, 39, 570-574.	0.8	9
30	Novel <i>NPM1</i> exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. Blood, 2021, 138, 2696-2701.	0.6	30
31	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Blood, 2021, 138, 2727-2730.	0.6	9
32	Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 729106.	1.3	1
33	A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML). Genes, 2021, 12, 1426.	1.0	3
34	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. Blood Advances, 2021, , .	2.5	14
35	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	3.3	57
36	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. Blood, 2021, 138, 1474-1474.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. <i>Blood</i> , 2021, 138, 635-635.	0.6	2
38	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	0.6	1
39	Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2204-2210.	2.0	15
40	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
41	NPM1-mutated acute myeloid leukemia: from bench to bedside. <i>Blood</i> , 2020, 136, 1707-1721.	0.6	152
42	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
43	Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. <i>Cell Chemical Biology</i> , 2020, 27, 678-697.e13.	2.5	27
44	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	2.0	12
45	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1
46	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
47	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
48	Mutations of the <i>XPO1</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. <i>Training/Validation Study</i> . <i>Blood</i> , 2020, 136, 31-32.	0.6	1
49	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
50	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020, 136, 54-55.	0.6	2
51	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. <i>Blood</i> , 2020, 136, 25-26.	0.6	3
52	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	1.2	14
53	GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. <i>Leukemia</i> , 2019, 33, 1827-1832.	3.3	13
54	Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 7540-7553.	3.2	20

#	ARTICLE	IF	CITATIONS
55	Germline NPM1 mutations lead to altered rRNA 2â€²-O-methylation and cause dyskeratosis congenita. <i>Nature Genetics</i> , 2019, 51, 1518-1529.	9.4	84
56	Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. <i>Annals of Hematology</i> , 2019, 98, 1507-1508.	0.8	1
57	Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520. <i>Blood</i> , 2019, 134, 407-407.	0.6	0
58	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. <i>Blood</i> , 2019, 134, 5485-5485.	0.6	1
59	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. <i>Blood</i> , 2019, 134, 4308-4308.	0.6	0
60	Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2018, 143, 958-970.	2.3	32
61	IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. <i>Cell Death and Disease</i> , 2018, 9, 1160.	2.7	22
62	Mutant NPM1 Maintains the Leukemic State through HOX Expression. <i>Cancer Cell</i> , 2018, 34, 499-512.e9.	7.7	209
63	NOTCH and Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1825.	2.2	10
64	NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. <i>Frontiers in Oncology</i> , 2018, 8, 105.	1.3	20
65	NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 229.	1.3	55
66	Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin. <i>Molecular Cytogenetics</i> , 2018, 11, 6.	0.4	3
67	The landscape of BRAF transcript and protein variants in human cancer. <i>Molecular Cancer</i> , 2017, 16, 85.	7.9	22
68	Wnt/ $\beta$ -Catenin Signaling Induces Integrin $\alpha$ 4 $\beta$ 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice. <i>Journal of Immunology</i> , 2017, 199, 3031-3041.	0.4	22
69	Clinical-Gradeâ€œExpanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cellâ€œDependent Graft-versus-Leukemia Effect in Murine Models. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1847-1851.	2.0	24
70	A scale of â€œbadâ€œ-co-mutations in NPM1-driven AML. <i>Blood</i> , 2017, 130, 1877-1879.	0.6	6
71	Ibrutinib Treatment of a Patient with Relapsing Chronic Lymphocytic Leukemia and Sustained Remission of Richter Syndrome. <i>Tumori</i> , 2017, 103, S37-S40.	0.6	4
72	Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses. <i>Blood</i> , 2016, 128, 1717-1717.	0.6	4

#	ARTICLE	IF	CITATIONS
73	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. <i>Blood</i> , 2015, 125, 1207-1216.	0.6	82
74	Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice. <i>Blood</i> , 2015, 126, 1790-1801.	0.6	58
75	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. <i>British Journal of Haematology</i> , 2015, 170, 305-322.	1.2	36
76	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. <i>Cancer Discovery</i> , 2015, 5, 396-409.	7.7	22
77	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. <i>Blood</i> , 2015, 125, 3455-3465.	0.6	124
78	Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. <i>Oncotarget</i> , 2015, 6, 16559-16572.	0.8	37
79	A novel NOTCH1 PEST domain mutation in a case of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1780-1782.	0.6	8
80	Notch1 modulates mesenchymal stem cells mediated regulatory T cell induction. <i>European Journal of Immunology</i> , 2013, 43, 182-187.	1.6	59
81	Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. <i>Blood Reviews</i> , 2013, 27, 13-22.	2.8	95
82	NOTCH and NF- $\kappa$ B interplay in chronic lymphocytic leukemia is independent of genetic lesion. <i>International Journal of Hematology</i> , 2013, 98, 153-157.	0.7	18
83	The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. <i>Blood</i> , 2013, 121, 3447-3458.	0.6	29
84	Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein $\beta$ Activity. <i>Journal of Biological Chemistry</i> , 2012, 287, 32728-32737.	1.6	17
85	T regulatory cell separation for clinical application. <i>Transfusion and Apheresis Science</i> , 2012, 47, 213-216.	0.5	38
86	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	13.9	949
87	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. <i>Blood</i> , 2011, 117, 3921-3928.	0.6	940
88	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 459-466.	0.7	40
89	Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. <i>Blood</i> , 2011, 117, 1109-1120.	0.6	210
90	CD4 <sup>+</sup> CD25 <sup>low</sup> GITR <sup>+</sup> cells: A novel human CD4 <sup>+</sup> T cell population with regulatory activity. <i>European Journal of Immunology</i> , 2011, 41, 2269-2278.	1.6	54

#	ARTICLE	IF	CITATIONS
91	Glucocorticoid-Induced TNFR family Related gene (GITR) enhances dendritic cell activity. Immunology Letters, 2011, 135, 24-33.	1.1	15
92	How Does the NPM1 Mutant Induce Leukemia?. Mental Illness, 2011, 3, e6.	0.8	4
93	Upregulation of eIF4E in Nucleophosmin 1 (NPM1) Haploinsufficient Cells Alters CCAAT Enhancer Binding Protein Alpha (C/EBP $\beta$ ) Activity: Implications for MDS and AML. Blood, 2011, 118, 2432-2432.	0.6	0
94	The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood, 2010, 115, 3341-3345.	0.6	82
95	<i>NOTCH1</i> PEST domain mutation is an adverse prognostic factor in $\text{B}\hat{\text{C}}\text{LL}$ . British Journal of Haematology, 2010, 151, 404-406.	1.2	97
96	Identification of the <i>miR-106b</i> ~ <i>miR-25</i> MicroRNA Cluster as a Proto-Oncogenic <i>PTEN</i> -Targeting Intron That Cooperates with Its Host Gene <i>MCM7</i> in Transformation. Science Signaling, 2010, 3, ra29.	1.6	390
97	Morgana/chp-1, a ROCK Inhibitor Involved in Centrosome Duplication and Tumorigenesis. Developmental Cell, 2010, 18, 486-495.	3.1	43
98	The Role of Nucleophosmin In Hematopoietic Stem Cells and the Pathogenesis of Myelodysplastic Syndrome. Blood, 2010, 116, 95-95.	0.6	5
99	Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. Cytotherapy, 2009, 11, 86-96.	0.3	3
100	Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Current Opinion in Oncology, 2009, 21, 573-581.	1.1	75
101	Nucleophosmin-1 Interacts with CCAAT Enhancer Binding Protein Alpha (C/EBP $\beta$ ) to Facilitate Granulocyte Maturation: Implications in MDS and AML. Blood, 2009, 114, 2768-2768.	0.6	0
102	Nucleophosmin Is Required for Macrophage Function and Maturation. Blood, 2009, 114, 238-238.	0.6	1
103	Mesenchymal cells recruit and regulate T regulatory cells. Experimental Hematology, 2008, 36, 309-318.	0.2	286
104	Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 2008, 111, 3859-3862.	0.6	120
105	Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/ $\hat{\text{a}}$ ) Mouse Bone Marrow as a Model for 5q- MDS. Blood, 2008, 112, 852-852.	0.6	0
106	Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. Leukemia and Lymphoma, 2007, 48, 923-930.	0.6	9
107	Interleukin-7 $\hat{\text{a}}$ Engineered Mesenchymal Cells: In Vitro Effects on Naive T-Cell Population. Biology of Blood and Marrow Transplantation, 2006, 12, 1250-1260.	2.0	9
108	Elucidating the Oncogenic Potential of NPMc+ In Vitro and In Vivo. Blood, 2006, 108, 12-12.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Interleukin 7-Engineered Stromal Cells: A New Approach for Hastening Naive T Cell Recruitment. Human Gene Therapy, 2005, 16, 752-764.	1.4	6